Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Non-Current Deffered Revenue: 2019-2024

Historic Non-Current Deffered Revenue for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $51.8 million.

  • Silence Therapeutics' Non-Current Deffered Revenue rose 173.37% to $55.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.3 million, marking a year-over-year increase of 173.37%. This contributed to the annual value of $51.8 million for FY2024, which is 30.95% down from last year.
  • Silence Therapeutics' Non-Current Deffered Revenue amounted to $51.8 million in FY2024, which was down 30.95% from $75.0 million recorded in FY2023.
  • Over the past 5 years, Silence Therapeutics' Non-Current Deffered Revenue peaked at $99.8 million during FY2021, and registered a low of $51.8 million during FY2024.
  • Its 3-year average for Non-Current Deffered Revenue is $68.5 million, with a median of $75.0 million in 2023.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first soared by 232.78% in 2020, then tumbled by 30.95% in 2024.
  • Silence Therapeutics' Non-Current Deffered Revenue (MRY) stood at $65.9 million in 2020, then surged by 51.31% to $99.8 million in 2021, then dropped by 21.24% to $78.6 million in 2022, then decreased by 4.54% to $75.0 million in 2023, then plummeted by 30.95% to $51.8 million in 2024.
  • Its Non-Current Deffered Revenue was $51.8 million in FY2024, compared to $75.0 million in FY2023 and $78.6 million in FY2022.